Colorectal peritoneal metastases: Optimal management review

doi:10.3748/wjg.v25.i27.3484

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 25, Issue 27

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (16946)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-5) series.

Item

Count

PDF

1156

WORD

286

HTML

12009

Figures (1-3)

249

Tables (1-5)

161

Sum=13861

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

492

Download

625

Sum=1117

Publishing Process of This Article

Item

Count

Browse

865

Download

1103

Sum=1968

Jul 21, 2019 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (68)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Opinion Review

World J Gastroenterol. Jul 21, 2019; 25(27): 3484-3502
Published online Jul 21, 2019. doi: 10.3748/wjg.v25.i27.3484

Table 3 Survival of patients with peritoneal metastases from colorectal cancer treated by cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy

Author/ Years/ Country	1-yr SR (%)	3-yr SR (%)	5-yr SR (%)	Mortality rate (%)	Morbidity rate (%)	Median OS (mo)	OS 95%CI (mo)	PFS 95%CI (mo)	DFS/RFS 95%CI (mo)	Follow-up times (range) (mo)
Controlled studies
Franko/2010/America[109]	92	51	28	NR	NR	34.7	NR	NR	NR	NR
Gervais/2013/Canada[110]	92	61	36	4	20	54	NR	NR	8	22.8 (2-81)
Goéré/2015/France[111]	90	52	32	5.8	29.5	35	NR	NR	NR	60 (47-74)
Huang/2014/China[112]	63.6	16	NR	0	28.6	13.7	10.0-16.5	NR	NR	41.5 (11.5-70.9)
HIPEC single arm studies
Cao/2009/Australia[113]	83.6	51.4	32.1	NR	NR	37.0	1-72	NR	NR	19 (1-72)
Ceelen/2014/Belgium[61]	75 (NNT) 75 (NCA) 96 (NCB)	39 (NNT) 30 (NCA) 71 (NCB)	25 (NNT) 13 (NCA)	NR	NR	25 (NNT) 22 (NCA) 39 (NCB) 30 (AC) 22 NAC)	19.1-30.9 (NNT) 12.9-31.1 (NCA) 17.6-60.4 (NCB) 20.7-39.3 (AC) 14.2-29.8 (NAC)	NR	NR	18
Elias/2014/France[53]	91.4	54	36.5	4.2	17	41	NR	NR	NR	62.4 (55.6-77.6)
Frøysnes/2016/Norway[114]	93	65	36	0	15.5	47	42-52	NR	10 (7-12)	45 (35-55)
Hamilton/2011/Canada[115]	79	38	34	NR	NR	27	0-87	NR	9 (0-87) 3-yr 34% 5-yr 26%	28 (0-119) (all)
Hompes/2012/Belgium[116]	97.9	84	NA	0	52.1	NA	NA	NR	19.8 (RFS)	22.7 (3.2- 55.7)
Passot/2016/France[117]	83	51	31	NR	30	36	NR	NR	11	NR
Prada-Villaverde/2014/Spain[118]	85	45	35	NR	NR	31.4	NR	NR	NR	NR
Quenet/2011/France[119]	92	36	44	4.1	47.2	41	32-60	NR	10.9 3-yr 15%	30.3 (2-88)

Adapted from Huang et al[112]. SR: Survival rate; OS: Overall survival; PFS: Progression-free survival; RFS: Recurrence-free survival; DFS: Disease-free survival; NA: Not achieved; NR: Not reported; NNT: Non-neoadjuvant therapy; NCA: Neoadjuvant chemotherapy alone; NCB: Neoadjuvant chemotherapy + bevacizumab; AC: Adjuvant chemotherapy; NAC: Non-adjuvant chemotherapy; CI: Confidence interval.

Citation: Sánchez-Hidalgo JM, Rodríguez-Ortiz L, Arjona-Sánchez Á, Rufián-Peña S, Casado-Adam Á, Cosano-Álvarez A, Briceño-Delgado J. Colorectal peritoneal metastases: Optimal management review. World J Gastroenterol 2019; 25(27): 3484-3502
URL: https://www.wjgnet.com/1007-9327/full/v25/i27/3484.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i27.3484